Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
By Elizabeth A. Thiele, Eric D. Marsh, Jacqueline A. French, M. Mazurkiewicz-Bełdzińska, S. Benbadis, Charuta N. Joshi, Paul D Lyons, A. Taylor, Claire Roberts, K. Sommerville. The Lancet, 2018
730 citations recorded by the source corpus.
Subfields: Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/eca4153db8e8445f07c1bd10328320f612ed5120
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
In Psychiatry and Mental health
Citations in the corpus
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome (2018, background): “Upper respiratory tract infection 11 (14) 11 (16) 11 (13)”